Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis) [0.03%]
中重度特应性皮炎患者应用度普利尤单抗或乌帕替尼的纵向反应轨迹：IL-AD（意大利特应性皮炎现状）多中心真实世界研究
Luca Potestio,Cataldo Patruno,Silvia Mariel Ferrucci et al.
Luca Potestio et al.
Introduction: Understanding how treatment responses evolve over time is essential for optimising therapeutic strategies in moderate-to-severe atopic dermatitis (AD). While clinical trials have demonstrated the efficacy of...
The Gut-Oral-Skin-Heart Microbiota Axis and Oxidative Stress: Where Have We Been and Where Are We Going [0.03%]
肠-口-皮肤-心脏微生物轴和氧化应激：我们从哪里来，要到哪里去？
Irena Girna,Alicja Kuban-Jankowska,Anna Jakubczyk-Slabicka et al.
Irena Girna et al.
Scientific interest in the relationship between cardiovascular disease and the human microbiome has grown substantially in recent years, with particular emphasis placed on the gut microbiota. Emerging evidence suggests, however, that distin...
Correction: Collagen, Curcumin, and Glutathione to Enhance Dermal Health with Declining Estrogen Levels in Aging Women-A Narrative Review [0.03%]
补遗：胶原蛋白、姜黄素和谷胱甘肽在女性衰老雌激素水平下降时增强皮肤健康的功效-叙述性综述
Priscila Arbex,Edwin D Lephart
Priscila Arbex
Published Erratum
Dermatology and therapy. 2026 Jun;16(6):2731. DOI:10.1007/s13555-026-01803-0 2026
Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study [0.03%]
生物制剂治疗持续时间对中重度银屑病临床治愈影响的队列研究
Che-Chia Hsu,Yu-Huei Huang,Tsen-Fang Tsai
Che-Chia Hsu
Introduction: Psoriasis is a chronic inflammatory disease that often requires long-term treatment. However, treatment interruption is common. Although several predictors of drug-free remission (DFR) have been reported, th...
The Importance of Achieving High Treatment Targets in Atopic Dermatitis: A Narrative Review [0.03%]
特应性皮炎治疗目标高疗效的实现意义：叙事综述
Antonio Costanzo,Giulia De Martino,Sara Di Fino et al.
Antonio Costanzo et al.
Atopic dermatitis (AD) is associated with a significant physical, psychological, social and economic burden and a decreased quality of life. There is a relationship between disease burden and the level of disease severity and control. The b...
Topical Timolol Beyond Infancy: A Retrospective Study of Its Use in Persistent Infantile Hemangiomas [0.03%]
噻吗洛尔用于治疗婴幼儿血管瘤的回顾性研究
Olga Bogomolets,Sofiia Bogomolets-Sheremetieva
Olga Bogomolets
Introduction: Infantile hemangiomas (IH) usually undergo spontaneous involution; however, some lesions remain visible after infancy and may cause psychosocial distress in children and their families. Evidence regarding th...
Biological Photoprotection: A Review of its Mechanisms, Evidence, and Clinical Implications [0.03%]
生物光防护：其机制、证据及临床意义的综述
Anthony Brown,Thierry Passeron,Yolanda Gilaberte et al.
Anthony Brown et al.
Biological photoprotection refers to the enhancement, preservation, or mimicry of the skin's intrinsic defense systems to prevent or mitigate damage induced by solar and environmental stressors. Unlike conventional sunscreens, which primari...
Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region [0.03%]
Upadacitinib治疗头颈部区域特应性皮炎患者的疗效
Kilian Eyerich,Pedro Mendes-Bastos,Gregor Holzer et al.
Kilian Eyerich et al.
Introduction: Head and neck atopic dermatitis (AD) is difficult to treat. We evaluated the efficacy of upadacitinib versus placebo in patients with head and neck AD in a post hoc analysis of Measure Up 1 (NCT03569293) and...
Angelo V Marzano,Falk G Bechara,Vivian Y Shi et al.
Angelo V Marzano et al.
Introduction: Hidradenitis suppurativa (HS) is a chronic, systemic, immune-mediated disease requiring multimodal care, which is crucial for raising awareness and advancing treatment. This project aimed to establish consen...
Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo [0.03%]
托法令临床试验3期试验方案介绍/评估托法令用于治疗非节段型白癜风成人及青少年患者的试验方案描述
Tatjana Lukic,Pranab Ghosh,Lynne Napatalung et al.
Tatjana Lukic et al.
Introduction: Ritlecitinib is an oral, selective inhibitor of JAK3 and TEC family kinases under investigation for the treatment of nonsegmental vitiligo (NSV). In a phase 2b study, ritlecitinib was efficacious and well to...